Background
==========

As the world's population ages, gastric cancer (GC) has become a very common cancer in elderly patients,[@b1-ott-11-1353],[@b2-ott-11-1353] especially in patients aged 65 years and older.[@b3-ott-11-1353],[@b4-ott-11-1353] Data on the clinicopathological features and prognosis of elderly GC patients are limited and controversial. It was indicated that poorly differentiated tumors were more common in elderly patients.[@b5-ott-11-1353] However, some studies indicated that younger patients exhibited a predominance of poorly differentiated tumor.[@b6-ott-11-1353],[@b7-ott-11-1353] Furthermore, it was reported that the prognosis of GC in the elderly was worse than that in nonelderly patients because of the aggressive biological behavior and poorly differentiated histology of the tumor.[@b8-ott-11-1353],[@b9-ott-11-1353] However, Zeeneldin et al[@b10-ott-11-1353] reported that the prognosis in elderly patients is equivalent to or better than that in nonelderly patients. Moreover, few studies have focused specifically on the clinicopathological features and prognosis of GC in elderly and middle-aged patients.

Against this background, we retrospectively analyzed the clinicopathological features and prognosis of elderly and middle-aged GC patients with curative surgical resection. The aim of this study was to identify the clinicopathological features and prognosis of GC in elderly patients.

Patients and methods
====================

Patients and data
-----------------

This study was performed in the Xijing Hospital of Digestive Diseases, affiliated with the Fourth Military Medical University. From May 2008 to December 2014, a total of 5,285 consecutive GC patients were enrolled in this study. To compare the prognosis of elderly and middle-aged patients, patients were selected using the inclusion criteria as follows: 1) had undergone a D2 gastrectomy; 2) had no neoadjuvant chemotherapy; 3) had no other type of tumor; and 4) had no distant metastasis.

In the present study, elderly patients were defined as those at the top quartile in the age histogram of GC, whereas middle-aged patients were defined as those within the 10 years range around the second quartile point.[@b11-ott-11-1353] The histogram for the 5,285 GC patients is shown in [Figure 1](#f1-ott-11-1353){ref-type="fig"}, and the top quartile for age included patients older than 65 years. Furthermore, in order to exclude the influence of senility on the overall survival, the elderly patients were defined as those aged 65--79 years. Thus, the elderly group included 815 patients with GC. The second quartile point for age was 58 years, and patients aged 55--64 years were the largest part of the histogram in our department. Therefore, the middle-aged cohort was composed of 1,096 patients aged 55--64 years.

The clinicopathological data including age, gender, tumor location, tumor size, histological type, tumor depth, lymph node metastasis, TNM stage, levels of carcinoembryonic antigen (CEA), alpha fetoprotein (AFP), carbohydrate antigen (CA) 19-9, and CA125 were recorded. The pathological staging was assessed according to the American Joint Committee on Cancer TNM classification of GC (7th edition, 2010). The patients received postoperative chemotherapy according to the NCCN guidelines of GC. A CEA level of ≤5 μg/L, an AFP level of ≤8.1 μg/L, a CA19-9 level of ≤27 U/mL, and a CA125 level of ≤35 μg/mL were considered to be normal. This study was approved by the Ethical Committee of Xijing Hospital, and written informed consent was obtained from all patients. All the patients were followed up twice a year until December 2015.

Statistical analysis
--------------------

Data were processed using SPSS 22.0 for Windows (IBM Corporation, Armonk, NY, USA). Discrete variables were analyzed using the Chi-square test or Fisher's exact test. Univariate and multivariate analyses were evaluated by Cox's proportional hazard regression. The overall survival was measured from the time of resection until death or last follow-up. Evaluation for overall survival was obtained by Kaplan--Meier method. *P*-values \<0.05 were considered statistically significant.

Results
=======

The clinicopathological features of elderly patients are summarized in [Table 1](#t1-ott-11-1353){ref-type="table"}. A total of 5,282 patients were retrospectively analyzed in the study. Among them, 1,381 patients between 65 and 79 years were classified as the elderly group (26.15%), and 1,848 patients between 55 and 64 years were classified as the middle-aged group (34.99%). The most common symptom in elderly patients was abdominal pain (54.31%), followed by abdominal distension (43.08%), dysphagia (19.12%), heartburn (14.55%), melena (9.56%), and vomiting (8.91%). The proportion of dysphagia was significantly higher in elderly patients than that in middle-aged patients (19.12% vs 15.04%, *P*=0.002), whereas the proportion of abdominal pain and heartburn were significantly lower in elderly patients than that in middle-aged patients (54.31% vs 62.72%, *P*\<0.001; 14.55% vs 17.26%, *P*=0.038, respectively). The most common location was upper third (37.94%), followed by lower third (37.65%) and middle third (15.35%). The proportion of patients with CA19-9 was significantly higher in elderly patients than that in middle-aged patients (24.82% vs 20.74%, *P*=0.009).

In order to further analyze the prognosis between middle-aged and elderly patients, patients were selected using the inclusion criteria described earlier, which is shown in [Figure 2A](#f2-ott-11-1353){ref-type="fig"} as a flowchart. Overall, 815 elderly patients and 1,096 patients in the middle-aged group were included. The clinicopathological features of the GC in these elderly and middle-aged patients with D2 gastrectomy are summarized in [Table 2](#t2-ott-11-1353){ref-type="table"}. There was no significant difference in clinicopathological features between elderly and middle-aged patients (all *P*\>0.05).

The risk factors for the prognosis of GC in elderly and middle-aged patients with D2 gastrectomy were analyzed using univariate and multivariate analyses. The results indicated that age, tumor location, tumor size, histological type, tumor depth, lymph node metastasis, TNM stage, type of resection, level of CEA, level of AFP, level of CA19-9, and level of CA125 were predictors for overall survival according to the univariate analysis. In addition, age, tumor size, histological type, tumor depth, lymph node metastasis, level of CEA, level of AFP, level of CA19-9, and level of CA125 were independent risk factors for prognosis by multivariate analysis ([Table 3](#t3-ott-11-1353){ref-type="table"}). Overall survival in the elderly group was significantly less than that in the middle-aged group (*P*=0.002, [Figure 2B](#f2-ott-11-1353){ref-type="fig"}).

As tumor size, histological type, TNM stage, CEA, AFP, CA19-9, and CA125 level were independent risk factors for the prognosis of GC patients, the overall survival between middle-aged and elderly patients was further analyzed within subgroups stratified by the predictors mentioned earlier. The prognosis for elderly patients was significantly worse than that for middle-aged patients with a tumor size \>5 cm (*P*=0.002, [Figure 3B](#f3-ott-11-1353){ref-type="fig"}), poorly differentiated status (*P*\<0.001, [Figure 4C](#f4-ott-11-1353){ref-type="fig"}), stage III tumor (*P*=0.002, [Figure 5C](#f5-ott-11-1353){ref-type="fig"}), normal CEA level (*P*=0.009, [Figure 6A](#f6-ott-11-1353){ref-type="fig"}), normal AFP level (*P*=0.002, [Figure 6B](#f6-ott-11-1353){ref-type="fig"}), normal CA19-9 level (*P*=0.002, [Figure 6C](#f6-ott-11-1353){ref-type="fig"}), and normal CA125 level (*P*=0.004, [Figure 6D](#f6-ott-11-1353){ref-type="fig"}). However, the prognosis of elderly patients was comparable to that of middle-aged patients when the tumor size was \<5 cm (*P*=0.510, [Figure 3A](#f3-ott-11-1353){ref-type="fig"}), with well or moderately differentiated status and mucinous or signet ring cell (*P*=0.974, *P*=0.566, and *P*=0.051, respectively, [Figure 4A, B, and D](#f4-ott-11-1353){ref-type="fig"}), stage I or II tumor (*P*=0.407 or *P*=0.338, respectively, [Figure 5A and B](#f5-ott-11-1353){ref-type="fig"}), elevated CEA level (*P*=0.093, [Figure 6A](#f6-ott-11-1353){ref-type="fig"}), elevated AFP level (*P*=0.459, [Figure 6B](#f6-ott-11-1353){ref-type="fig"}), elevated CA19-9 level (*P*=0.494, [Figure 6C](#f6-ott-11-1353){ref-type="fig"}), and elevated CA125 level (*P*=0.183, [Figure 6D](#f6-ott-11-1353){ref-type="fig"}).

Discussion
==========

Data on the clinicopathological features and prognosis of elderly GC patients are limited and controversial. In the present study, the clinicopathological features were comparable between elderly and middle-aged GC patients. Age was an independent risk factor for the prognosis of GC, and the prognosis for elderly patients was significantly worse than that for middle-aged patients.

It is widely accepted that the proportion of elderly patients is increasing gradually. Takatsu et al[@b11-ott-11-1353] reported that GC usually occurred in individuals aged 60--69 years in Japan. However, our results showed that GC was mainly distributed in patients between 55 and 64 years, which were younger than that in Japan. This may be due to more chronic infection, tobacco smoking, or environmental pollution in China.[@b3-ott-11-1353],[@b12-ott-11-1353],[@b13-ott-11-1353] The definition of elderly varied among previous reports, which have classified aged as \>70, \>75, and \>80 years.[@b8-ott-11-1353],[@b10-ott-11-1353],[@b14-ott-11-1353],[@b15-ott-11-1353] In our present study, the top quartile of age was \>65 years. Moreover, considering the comorbidities associated with very old patients who might influence the prognosis, elderly patients in our present study were defined as those aged 65--79 years. However, the comorbidity in elderly and middle-aged patients and the influence of comorbidity on prognosis were not analyzed in our present study. This requires further investigation.

Previously, the comparison of clinicopathological features has been mainly analyzed between the elderly and young GC patients.[@b11-ott-11-1353],[@b16-ott-11-1353] However, no study has focused on the clinicopathological features between elderly and middle-aged patients. According to previous reports,[@b17-ott-11-1353]--[@b19-ott-11-1353] the lower third was the most common location for GC in elderly patients. However, tumors located in the upper third were more common in elderly patients in our present study. It is well known that cardiac cancer was associated with gastroesophageal reflux disease (GERD).[@b20-ott-11-1353],[@b21-ott-11-1353] Moreover, the incidence of GERD increased with age, which was a risk factor for GERD.[@b22-ott-11-1353],[@b23-ott-11-1353] This may, to some extent, explain the different distribution of tumors in elderly GC patients.

We have confirmed that GC in the elderly is characterized by specific clinicopathological features, including male predominance, poor differentiation, and larger tumor size, which are consistent with previous studies.[@b5-ott-11-1353],[@b24-ott-11-1353],[@b25-ott-11-1353] The reason for male predominance remains unclear. It may be related to the greater susceptibility of male patients to *Helicobacter pylori* infection, alcohol consumption, and smoking.[@b26-ott-11-1353],[@b27-ott-11-1353] Infection with *H. pylori* and alcohol consumption have been associated with an increased risk for GC.[@b27-ott-11-1353],[@b28-ott-11-1353] In the present study, the proportion of dysphagia was significantly higher and the proportion of abdominal pain were significantly lower in elderly patients than that in the middle-aged group. Patients with stage III tumors comprised 42.65% of elderly patients, which was \>13.7%--29.3% reported in previous studies.[@b5-ott-11-1353],[@b29-ott-11-1353] These may be partially due to hidden clinical manifestations and lack of obvious symptoms in elderly patients with early stage tumors.[@b18-ott-11-1353] Moreover, Liang et al[@b25-ott-11-1353] reported that the lack of a comprehensive system for tumor screening in China may also result in late diagnosis of GC in elderly patients. It was reported that positive rates of preoperative serum CEA, AFP, CA19-9, and CA125 tended to be higher in elderly patients than that in nonelderly patients.[@b30-ott-11-1353]--[@b32-ott-11-1353] However, the positive rates of these tumor markers except CA19-9 were not comparable between elderly and middle-aged patients in our present study. This may be a result of differences in race, sample size, and population.

It was reported that the overall survival of elderly patients was significantly less than that of nonelderly patients.[@b33-ott-11-1353],[@b34-ott-11-1353] In our present study, we also found that age was an independent risk factor for the prognosis of GC patients. However, the prognoses were not comparable between the two groups with tumor sizes \<5 cm, well and moderately differentiated status, stage I and II tumors, elevated CEA level, elevated AFP level, elevated CA19-9 level, and elevated CA125 level. These issues require further investigation.

Treatment for elderly GC patients has been criticized.[@b35-ott-11-1353] Factors such as comorbidity and decreased functional status may influence the selection of treatment strategies for elderly patients. One of the main concerns with gastrectomy in the elderly is palliative operation or radical dissection. Elderly patients are considered to be high risk for major surgery because of decreasing functional status. Thus, the Japanese guidelines for GC suggest that R0 resection with at least limited lymph node dissection should be considered as the first choice treatment for elderly GC patients.[@b36-ott-11-1353] Takeshita et al[@b17-ott-11-1353] also reported that limited lymph node dissection in elderly patients did not decrease overall survival of GC patients. However, several studies have reported that complications related surgery could be reduced and prognosis could be improved in elderly patients following advances in surgical and anesthesiological techniques.[@b9-ott-11-1353],[@b29-ott-11-1353],[@b37-ott-11-1353] Thus, the optimal extent of lymphadenectomy during gastrectomy needs further investigations for elderly GC patients.

There are some limitations to the present study. First, the retrospective design in a single center might lead to selection bias. Second, the data for comorbidities in elderly and middle-aged patients and the influence of comorbidities on prognosis were not analyzed. These questions require further investigation.

Conclusion
==========

The clinicopathological features of elderly patients were different to those of middle-aged patients. The prognosis of elderly GC patients with D2 gastrectomy was significantly worse than that of middle-aged patients, especially in patients with a tumor of \>5 cm, a poorly differentiated tumor, a stage III tumor, or normal levels of CEA, AFP, CA19-9, or CA125.
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![Distribution of all gastric cancers along with age.](ott-11-1353Fig1){#f1-ott-11-1353}

![Flowchart of selection process (**A**) and overall survival between middle-aged and elderly patients with D2 gastrectomy (**B**).](ott-11-1353Fig2){#f2-ott-11-1353}

![Overall survival of patients based on tumor size.\
**Note:** The overall survival for elderly and middle-aged patients with tumor size \<5 cm (**A**) and \>5 cm (**B**).](ott-11-1353Fig3){#f3-ott-11-1353}

###### 

Overall survival of patients based on histological type.

**Note:** The overall survival for elderly and middle-aged patients with well-differentiated status (**A**), moderately differentiated status (**B**), poorly differentiated status (**C**), and mucinous or signet ring cell status (**D**).
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![Overall survival of patients based on TNM stage.\
**Note:** The overall survival for elderly and middle-aged patients with stage I tumor (**A**), stage II tumor (**B**), and stage III tumor (**C**).](ott-11-1353Fig5){#f5-ott-11-1353}

![Overall survival of patients based on tumor markers.\
**Note:** The overall survival for elderly and middle-aged patients with normal and elevated CEA level (**A**), normal and elevated AFP level (**B**), normal and elevated CA19-9 level (**C**), and normal and elevated CA125 level (**D**).\
**Abbreviations:** AFP, alpha fetoprotein; CA, carbohydrate antigen; CEA, carcinoembryonic antigen.](ott-11-1353Fig6){#f6-ott-11-1353}

###### 

Clinicopathological characteristics of middle-aged and elderly gastric cancer patients

  Characteristics                                                                       Elderly group (n=1,381)   Middle-aged group (n=1,848)   *P*-value
  ------------------------------------------------------------------------------------- ------------------------- ----------------------------- -----------
  Age (years), median (range)                                                           69 (65--79)               59 (55--64)                   
  Gender, n (%)                                                                                                                                 0.992
   Male                                                                                 1,120 (81.10)             1,499 (81.11)                 
   Female                                                                               261 (18.90)               349 (18.89)                   
  Abdominal pain, n (%)                                                                                                                         \<0.001
   Negative                                                                             631 (45.69)               689 (37.28)                   
   Positive                                                                             750 (54.31)               1,159 (62.72)                 
  Abdominal distension, n (%)                                                                                                                   0.575
   Negative                                                                             786 (56.92)               1,070 (57.90)                 
   Positive                                                                             595 (43.08)               778 (42.10)                   
  Dysphagia, n (%)                                                                                                                              0.002
   Negative                                                                             1,117 (80.88)             1,570 (84.96)                 
   Positive                                                                             264 (19.12)               278 (15.04)                   
  Vomiting, n (%)                                                                                                                               0.050
   Negative                                                                             1,258 (91.09)             1,718 (92.97)                 
   Positive                                                                             123 (8.91)                130 (7.03)                    
  Heartburn, n (%)                                                                                                                              0.038
   Negative                                                                             1,180 (85.45)             1,529 (82.74)                 
   Positive                                                                             201 (14.55)               319 (17.26)                   
  Melena, n (%)                                                                                                                                 0.974
   Negative                                                                             1,249 (90.44)             1,672 (90.48)                 
   Positive                                                                             132 (9.56)                176 (9.52)                    
  Surgical procedures, n (%)                                                                                                                    0.937
   Radical operation                                                                    1,223 (88.56)             1,630 (88.20)                 
   Palliative operation                                                                 71 (5.14)                 100 (5.41)                    
   Exploratory operation                                                                87 (6.30)                 118 (6.39)                    
  Tumor location, n (%)                                                                                                                         \<0.001
   Upper third                                                                          524 (37.94)               582 (31.49)                   
   Middle third                                                                         212 (15.35)               371 (20.08)                   
   Lower third                                                                          520 (37.65)               722 (39.07)                   
   Two-thirds or more                                                                   125 (9.05)                173 (9.36)                    
  Tumor size (cm), n (%)                                                                                                                        0.086
   \<5                                                                                  597 (43.23)               855 (46.27)                   
   ≥5                                                                                   784 (56.77)               993 (53.73)                   
  Histologic type (*Σ*[a](#tfn1-ott-11-1353){ref-type="table-fn"}=3,024), n (%)                                                                 0.472
   Well differentiated                                                                  182 (14.06)               213 (12.31)                   
   Moderately differentiated                                                            396 (30.60)               526 (30.40)                   
   Poorly differentiated                                                                631 (48.76)               865 (50.00)                   
   Mucinous or signet ring cell                                                         85 (6.57)                 126 (7.28)                    
  Tumor depth[b](#tfn2-ott-11-1353){ref-type="table-fn"} (*Σ*=3,024), n (%)                                                                     0.350
   Tis + T1                                                                             199 (15.38)               300 (17.34)                   
   T2                                                                                   207 (16.00)               249 (14.39)                   
   T3                                                                                   464 (35.86)               631 (36.47)                   
   T4                                                                                   424 (32.77)               550 (31.79)                   
  Lymph node metastasis[b](#tfn2-ott-11-1353){ref-type="table-fn"} (*Σ*=3,024), n (%)                                                           0.592
   N0                                                                                   468 (36.17)               617 (35.66)                   
   N1                                                                                   231 (17.85)               329 (19.02)                   
   N2                                                                                   223 (12.23)               317 (18.32)                   
   N3                                                                                   372 (28.75)               467 (26.99)                   
  TNM stage[b](#tfn2-ott-11-1353){ref-type="table-fn"} (*Σ*=3,108), n (%)                                                                       0.282
   I                                                                                    273 (20.57)               403 (22.63)                   
   II                                                                                   386 (29.09)               534 (29.98)                   
   III                                                                                  566 (42.65)               701 (39.35)                   
   IV                                                                                   102 (7.69)                143 (8.04)                    
  CEA (*Σ*=2,962), n (%)                                                                                                                        0.270
   Negative                                                                             944 (74.92)               1,305 (76.67)                 
   Positive                                                                             316 (25.08)               397 (23.33)                   
  AFP (*Σ*=2,854), n (%)                                                                                                                        0.411
   Negative                                                                             1,142 (94.54)             1,544 (93.80)                 
   Positive                                                                             66 (5.46)                 102 (6.20)                    
  CA19-9 (*Σ*=2,892), n (%)                                                                                                                     0.009
   Negative                                                                             927 (75.62)               1,315 (79.26)                 
   Positive                                                                             306 (24.82)               344 (20.74)                   
  CA125 (*Σ*=2,808), n (%)                                                                                                                      0.554
   Negative                                                                             1,107 (92.33)             1,495 (92.91)                 
   Positive                                                                             92 (7.67)                 114 (7.09)                    

**Notes:**

Owing to data acquisition, completeness of data is limited.

Seventh UICC/AJCC TNM classification for gastric cancer.

**Abbreviations:** AFP, alpha fetoprotein; CA, carbohydrate antigen; CEA, carcino-embryonic antigen; UICC/AJCC, Union for International Cancer Control/American Joint Committee on Cancer.

###### 

Clinicopathological characteristics of middle-aged and elderly patients with D2 gastrectomy

  Characteristics                                                           Elderly group (n=815)   Middle-aged group (n=1,096)   *P*-value
  ------------------------------------------------------------------------- ----------------------- ----------------------------- -----------
  Age (years), median (range)                                               70 (65--79)             59 (55--64)                   
  Gender, n (%)                                                                                                                   0.435
   Male                                                                     654 (80.25)             895 (81.66)                   
   Female                                                                   161 (19.75)             201 (18.34)                   
  Tumor location, n (%)                                                                                                           0.304
   Upper third                                                              325 (39.88)             396 (36.13)                   
   Middle third                                                             181 (22.21)             242 (22.08)                   
   Lower third                                                              298 (36.56)             444 (40.51)                   
   Two-thirds or more                                                       11 (1.35)               14 (1.28)                     
  Tumor size (cm), n (%)                                                                                                          0.216
   \<5                                                                      379 (46.50)             541 (49.36)                   
   ≥5                                                                       436 (53.50)             555 (50.64)                   
  Histologic type, n (%)                                                                                                          0.423
   Well differentiated                                                      107 (13.13)             123 (11.22)                   
   Moderate differentiated                                                  252 (30.92)             323 (29.47)                   
   Poorly differentiated                                                    415 (50.92)             587 (53.56)                   
   Mucinous or signet ring cell                                             41 (5.03)               63 (5.75)                     
  Tumor depth,[a](#tfn4-ott-11-1353){ref-type="table-fn"} n (%)                                                                   0.623
   Tis + T1                                                                 128 (15.71)             192 (17.52)                   
   T2                                                                       117 (14.36)             168 (15.33)                   
   T3                                                                       300 (36.81)             390 (35.58)                   
   T4                                                                       270 (33.13)             346 (31.57)                   
  Lymph node metastasis,[a](#tfn4-ott-11-1353){ref-type="table-fn"} n (%)                                                         0.241
   N0                                                                       298 (36.56)             392 (35.77)                   
   N1                                                                       138 (16.93)             205 (18.70)                   
   N2                                                                       134 (16.44)             206 (18.80)                   
   N3                                                                       245 (30.06)             293 (26.73)                   
  TNM stage,[a](#tfn4-ott-11-1353){ref-type="table-fn"} n (%)                                                                     0.671
   I                                                                        185 (22.70)             268 (24.45)                   
   II                                                                       232 (28.47)             306 (27.92)                   
   III                                                                      398 (48.83)             522 (47.63)                   
  Type of resection, n (%)                                                                                                        0.343
   Proximal gastrectomy                                                     95 (11.66)              126 (11.50)                   
   Distal gastrectomy                                                       287 (35.21)             421 (38.41)                   
   Total gastrectomy                                                        433 (53.13)             549 (50.09)                   
  CEA, n (%)                                                                                                                      0.991
   Negative                                                                 633 (77.67)             851 (77.65)                   
   Positive                                                                 182 (22.33)             245 (22.35)                   
  AFP, n (%)                                                                                                                      0.240
   Negative                                                                 774 (94.97)             1,027 (93.70)                 
   Positive                                                                 41 (5.03)               69 (6.30)                     
  CA19-9, n (%)                                                                                                                   0.251
   Negative                                                                 633 (77.67)             875 (79.84)                   
   Positive                                                                 182 (22.33)             221 (20.16)                   
  CA125, n (%)                                                                                                                    0.703
   Negative                                                                 774 (94.97)             1,045 (95.35)                 
   Positive                                                                 41 (5.03)               51 (4.65)                     

**Note:**

Seventh UICC/AJCC TNM classification for gastric cancer.

**Abbreviations:** AFP, alpha fetoprotein; CA, carbohydrate antigen; CEA, carcino-embryonic antigen; UICC/AJCC, Union for International Cancer Control/American Joint Committee on Cancer.

###### 

Univariate and multivariate analyses of prognostic factors for patients with D2 gastrectomy

  Parameter                                                          Univariate analysis   Multivariate analysis                                           
  ------------------------------------------------------------------ --------------------- ----------------------- ------- -------- ---------------------- -------
  Age                                                                0.259                 1.295 (1.102--1.522)    0.002   0.259    1.296 (1.102--1.524)   0.002
  Gender                                                             0.022                 1.023 (0.834--1.254)    0.830   −0.088   0.916 (0.744--1.127)   0.406
  Tumor location                                                     −0.093                0.911 (0.832--0.996)    0.042   −0.001   0.999 (0.911--1.096)   0.989
  Tumor size                                                         1.143                 3.135 (2.616--3.757)    0.000   0.439    1.551 (1.272--1.891)   0.000
  Histologic type                                                    −0.245                0.783 (0.708--0.866)    0.000   −0.106   0.899 (0.817--0.989)   0.029
  Tumor depth[a](#tfn6-ott-11-1353){ref-type="table-fn"}             0.827                 2.287 (2.060--2.539)    0.000   0.469    1.599 (1.363--1.875)   0.000
  Lymph node metastasis[a](#tfn6-ott-11-1353){ref-type="table-fn"}   0.676                 1.965 (1.824--2.117)    0.000   0.466    1.593 (1.401--1.812)   0.000
  TNM stage[a](#tfn6-ott-11-1353){ref-type="table-fn"}               1.182                 3.260 (2.828--3.760)    0.000   −0.065   0.937 (0.692--1.268)   0.672
  Type of resection                                                  −0.441                0.643 (0.566--0.731)    0.000   0.071    1.073 (0.937--1.228)   0.306
  CEA                                                                0.836                 2.307 (1.941--2.742)    0.000   0.353    1.424 (1.183--1.715)   0.000
  AFP                                                                0.640                 1.897 (1.444--2.493)    0.000   0.311    1.365 (1.030--1.809)   0.030
  CA199                                                              0.692                 1.998 (1.677--2.380)    0.000   0.280    1.324 (1.102--1.591)   0.003
  CA125                                                              1.244                 3.469 (2.624--4.585)    0.000   0.754    2.125 (1.601--2.821)   0.000

**Note:**

Seventh UICC/AJCC TNM classification for gastric cancer.

**Abbreviations:** AFP, alpha fetoprotein; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; HR, hazard ratio; UICC/AJCC, Union for International Cancer Control/American Joint Committee on Cancer.
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